Tempest Therapeutics Enters Agreement With Roche To Advance Evaluation Of Amezalpat Combination Therapy
Tempest Therapeutics Enters Agreement With Roche To Advance Evaluation Of Amezalpat Combination Therapy
Tempest Therapeutics与罗氏达成协议，推进Amezalpat联合疗法评估
Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. This agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study. Tempest retains all development and commercial rights to amezalpat.
根据协议，罗氏将在全球范围内提供atezolizumab，而Tempest将赞助并领导关键研究。该协议是基于两家公司之间的临床合作，根据该合作，amezalpat与atezolizumab和bevacizumab在一线HCC患者中结合，并与atezolizumab和bevacizumab单独在随机分组的第1b/2期研究中进行比较。Tempest保留amezalpat的所有开发和商业权利。